Abstract
Ten children with hematologic malignancies or a storage disease underwent transplantation using cord blood cells from an unrelated donor mismatched for 1 (n = 7) or 2 (n = 3) HLA antigens. The median total nucleated cell dose was 4.0 (range, 2.2–7.1) × 107/kg. GVHD prophylaxis consisted of tacrolimus dose-adjusted to maintain a whole blood level of 5–15 ng/ml with or without methotrexate 5 mg/m2 i.v. on days 1, 3, 6 and 11. Corticosteroids were not administered prophylactically. Median follow-up is 12 months (range, 5–28 months). One patient had autologous recovery and subsequently relapsed 153 days post transplant. For the remainder of the patients, the median time to an ANC >0.5 × 109/l was 21 days (range, 19–38 days), and the median time to platelets >20 × 109/l was 39 days (range, 21–97 days). The actuarial risk of grade 2 GVHD was 77% (95% CI, 49–100%), and no patient had grades 3–4 GVHD. Two patients developed chronic GVHD. The survival rate is 90% (95% CI, 81–100%). The combination of tacrolimus and minidose methotrexate is active for the prevention of severe but not moderate acute GVHD after mismatched unrelated donor cord blood transplantation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Przepiorka, D., Petropoulos, D., Mullen, C. et al. Tacrolimus for prevention of graft-versus-host disease after mismatched unrelated donor cord blood transplantation. Bone Marrow Transplant 23, 1291–1295 (1999). https://doi.org/10.1038/sj.bmt.1701807
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701807
Keywords
This article is cited by
-
GVHD prophylaxis by tacrolimus and mini-MTX in single-unit CBT: a single institute experience
International Journal of Hematology (2020)
-
Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults
Bone Marrow Transplantation (2007)
-
Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies
Bone Marrow Transplantation (2006)
-
Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation
Bone Marrow Transplantation (2000)
-
Tacrolimus clearance is age-dependent within the pediatric population
Bone Marrow Transplantation (2000)